These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 23741070)

  • 1. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma.
    Feng Y; Roy A; Masson E; Chen TT; Humphrey R; Weber JS
    Clin Cancer Res; 2013 Jul; 19(14):3977-86. PubMed ID: 23741070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma.
    Yamazaki N; Kiyohara Y; Uhara H; Fukushima S; Uchi H; Shibagaki N; Tsutsumida A; Yoshikawa S; Okuyama R; Ito Y; Tokudome T
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):997-1004. PubMed ID: 26410424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma.
    Weber JS; Dummer R; de Pril V; Lebbé C; Hodi FS;
    Cancer; 2013 May; 119(9):1675-82. PubMed ID: 23400564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.
    Weber J; Thompson JA; Hamid O; Minor D; Amin A; Ron I; Ridolfi R; Assi H; Maraveyas A; Berman D; Siegel J; O'Day SJ
    Clin Cancer Res; 2009 Sep; 15(17):5591-8. PubMed ID: 19671877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
    Schadendorf D; Hodi FS; Robert C; Weber JS; Margolin K; Hamid O; Patt D; Chen TT; Berman DM; Wolchok JD
    J Clin Oncol; 2015 Jun; 33(17):1889-94. PubMed ID: 25667295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.
    Zimmer L; Vaubel J; Mohr P; Hauschild A; Utikal J; Simon J; Garbe C; Herbst R; Enk A; Kämpgen E; Livingstone E; Bluhm L; Rompel R; Griewank KG; Fluck M; Schilling B; Schadendorf D
    PLoS One; 2015; 10(3):e0118564. PubMed ID: 25761109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ipilimumab: in previously treated patients with advanced melanoma.
    Sanford M
    BioDrugs; 2012 Jun; 26(3):185-93. PubMed ID: 22530681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.
    Horvat TZ; Adel NG; Dang TO; Momtaz P; Postow MA; Callahan MK; Carvajal RD; Dickson MA; D'Angelo SP; Woo KM; Panageas KS; Wolchok JD; Chapman PB
    J Clin Oncol; 2015 Oct; 33(28):3193-8. PubMed ID: 26282644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.
    Tirumani SH; Ramaiya NH; Keraliya A; Bailey ND; Ott PA; Hodi FS; Nishino M
    Cancer Immunol Res; 2015 Oct; 3(10):1185-92. PubMed ID: 26100356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.
    Johnson DB; Sullivan RJ; Ott PA; Carlino MS; Khushalani NI; Ye F; Guminski A; Puzanov I; Lawrence DP; Buchbinder EI; Mudigonda T; Spencer K; Bender C; Lee J; Kaufman HL; Menzies AM; Hassel JC; Mehnert JM; Sosman JA; Long GV; Clark JI
    JAMA Oncol; 2016 Feb; 2(2):234-40. PubMed ID: 26633184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial.
    Weber JS; Amin A; Minor D; Siegel J; Berman D; O'Day SJ
    Melanoma Res; 2011 Dec; 21(6):530-4. PubMed ID: 22051508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma.
    Luke JJ; Donahue H; Nishino M; Giobbie-Hurder A; Davis M; Bailey N; Ott PA; Hodi FS
    Cancer Immunol Res; 2015 Sep; 3(9):986-91. PubMed ID: 25943535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.
    Weber J
    Oncologist; 2007 Jul; 12(7):864-72. PubMed ID: 17673617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions.
    Eigentler TK; Schlaak M; Hassel JC; Loquai C; Stoffels I; Gutzmer R; Pätzold S; Mohr P; Keller U; Starz H; Ulrich J; Tsianakas A; Kähler K; Hauschild A; Janssen E; Schuler-Thurner B; Weide B; Garbe C
    J Immunother; 2014 Sep; 37(7):374-81. PubMed ID: 25075567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
    Graziani G; Tentori L; Navarra P
    Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial.
    Thompson JA; Hamid O; Minor D; Amin A; Ron IG; Ridolfi R; Assi H; Berman D; Siegel J; Weber JS
    J Immunother; 2012 Jan; 35(1):73-7. PubMed ID: 22130164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma.
    Wilgenhof S; Du Four S; Vandenbroucke F; Everaert H; Salmon I; Liénard D; Marmol VD; Neyns B
    J Immunother; 2013 Apr; 36(3):215-22. PubMed ID: 23502769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ipilimumab in advanced melanoma: reports of long-lasting responses.
    Farolfi A; Ridolfi L; Guidoboni M; Nicoletti SV; Piciucchi S; Valmorri L; Costantini M; Scarpi E; Amadori D; Ridolfi R
    Melanoma Res; 2012 Jun; 22(3):263-70. PubMed ID: 22516968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
    Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
    Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events.
    Shahabi V; Berman D; Chasalow SD; Wang L; Tsuchihashi Z; Hu B; Panting L; Jure-Kunkel M; Ji RR
    J Transl Med; 2013 Mar; 11():75. PubMed ID: 23521917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.